Highlights from ASCO: Advances in Multiple Myeloma   Impact of Novel anti-CD38 mAb Combination Therapies

Highlights from ASCO: Advances in Multiple Myeloma Impact of Novel anti-CD38 mAb Combination Therapies

Hear Dr. Shaji Kumar summarize and interpret key presentations, abstracts, and posters from a summer oncology conference. Highlights include the most recent data on CD38-directed monoclonal antibodies in newly diagnosed multiple myeloma and discuss their potential implications on clinical practice.

  • Provider:Haymarket Medical Education
  • Activity Link: https://www.mycme.com/courses/multiple-myeloma-novel-anti-cd38-mab-combination-therapies-9648
  • Start Date: 2024-08-30 05:00:00
  • End Date: 2024-08-30 05:00:00
  • Credit Details: IPCE Credits: 0.5 hours
    AMA PRA Category 1 Credit™️: 0.5 hours
  • Commercial Support: Source: Bristol-Myers Squibb Company - Amount: 100000.0 - Is Kind Support: False
  • Activity Type: Enduring Material
  • CME Finder Type: Online Learning
  • Fee to Participate: No, it's free
  • Measured Outcome: Learner Knowledge, Learner/Team Competence, Learner/Team Performance
  • Provider Ship: Directly Provided
  • Registration: Open to all
«
»
Subscribe
Notify of
guest
0 Comments
Oldest
Newest Most Voted
Inline Feedbacks
View all comments
0
Would love your thoughts, please comment.x
()
x

Contact us

If you want to join leaders who will shape what Americans think about sleep.

Name(Required)
Sign Up
This field is for validation purposes and should be left unchanged.

Sign up for the expert list

for media inquiries

Name(Required)
Sign Up
This field is for validation purposes and should be left unchanged.